Objective: To demonstrate the clinical course in a young female with gonadotroph adenoma causing ovarian stimulation. Patient and methods: Our patient was a 23-year-old woman with a history of oligomenorrhea who had previously undergone bilateral ovarian wedge resection owing to the clinical appearance of polycystic ovaries. Two years later, she sought treatment for headache, galactorrhea, history of spotting and lower abdominal distension. FSH, LH, b-LH, inhibin A and B, estradiol, prolactin (PRL), and bchorionic gonadotrophin (b-CG) were measured, and the responses of FSH, LH and b-LH to thyrotrophin-releasing hormone (TRH) were documented. Immunohistochemical analysis of the tumor tissue was performed after surgery. Five years after the trans-sphenoidal surgery, the patient again became oligomenorrheic. A large recurrent adenoma was diagnosed on CT one year later. Transvaginal ultrasound showed ovaries of normal size with multiple small cystic formations simulating a polycystic pattern, While the patient was awaiting surgery, a pituitary apoplexy occurred. Emergency decompressive surgery was performed and the patient fully recovered. Results: Enlarged ovaries were found on ultrasound examination simulating a hyperstimulationlike pattern. At that time, elevated levels of FSH (13.4 IU/l) and marginally elevated levels of b-LH (1.43 ng/ml) were found, whereas the level of LH (0.5 IU/l) was subnormal. Plasma estradiol was markedly supranormal (6150 pmol/l). Levels of inhibin A and B were elevated (326 pg/ml and 588 pg/ml respectively). The prolactin level (70 ng/ml) was increased, whereas b-chorionic gonadotrophin (b-CG) was normal. Signi®cantly increased FSH, LH, and b-LH responses to TRH stimulation were documented. Pituitary macroadenoma was found on MRI scan and removed by trans-sphenoidal surgery. Immunohistochemical examination showed high positivity for b-CG and LH, and slight positivity for FSH. Five years after the surgery, estradiol was elevated (1160 pmol/l), whereas basal levels of LH (4.65 IU/l) and FSH (3.98 IU/l) were not suppressed. After the second operation, immunostaining of the adenoma tissue con®rmed the previous ®ndings. Conclusions: Measurement of gonadotrophins in our case did not prove to be a method for identifying a large recurrent gonadotroph pituitary adenoma. The sonographic ovarian imaging varied from a polycystic-to an ovarian hyperstimulation-like pattern during the evolution of the tumour.
Five children with adrenocorticotropic hormone (ACTH) insensitivity associated with autonomic nervous system disorders are described. At the time of diagnosis, four of them had osteoporosis. The fifth patient died and skeletal roentgenograms were not done. Osteoporosis was subsequently discovered in one of our previously reported patients with ACTH insensitivity. We assume that osteoporosis is, at least partly, the result of decreased adrenal androgen production. Human leucocyte antigen typing failed to establish any linkage.
Nonclassic steroid 21-hydroxylase deficiency is an attenuated adrenal enzyme defect that is commonly the basis of hyperandrogenic syndromes. Inherited as an autosomal recessive trait, it is known to occur with high frequency in the general population and with increased frequency in a number of ethnic groups, including the Yugoslav population. Following expansion of the original data on 21 families in Croatia to a total of 49 Croatian and Serbian families, we establish that this enzymatic disorder is increased in this Slavic population and provide an updated estimate for the gene frequency of 0.092 (0.035\x=req-\ 0.149). Also in keeping with earlier reports, we continue to note the absence of association between nonclassic 21\ x=r eq-\ hydroxylase deficiency occurring among Yugoslavs and HLA-B14;DR1.Nonclassic steroid 21-hydroxylase deficiency is an autosomal recessive disorder that is known to occur with very high frequency generally, and which in addition shows increased prevalence in certain ethnic populations (1). This partial adrenal enzyme defect may or may not be clinically manifest in af¬ fected individuals, but can be identified by hor¬ mone criteria. Mild to moderate elevations of serum androgens result from increased secretion by the adrenal of androgens and of androgenic precursors which undergo peripheral conversion to active hormones. Biochemical indices of reduced adrenal 21-hydroxylation are serum elevations of the steroid intermediates 17a-hydroxyprogesterone (17-OHP), the principal substrate of 21-hy-droxylase, which fails to be converted to 11-deoxycortisol (compound S), the direct precursor of Cor¬ tisol, and also of A4-androstenedione (A4-A), im¬ mediately distal to 17-OHP in the androgenic pathway. Clinical effects arising from 21-hydroxy¬ lase deficiency vary between individuals and the different ages within the same individual.The first population genetic study on nonclassic 21-hydroxylase deficiency (1) identified an in¬ creased incidence among Yugoslavs, estimating the gene frequency among this population to be 0.125 (0.042-0.268 (95% confidence limits)) based on data from 21 families in Zagreb, SR Croatia, Yu¬ goslavia (1). This study observed that positive link¬ age disequilibrium between nonclassic 21-hydroxy¬ lase deficiency and HLA-B14;DR1 existing in other ethnic groups at increased risk, Ashkenazic Jews, Hispanics, and Italians, was absent in the Yu¬ goslav patient group.The population genetic analysis of the original study in 167 families was based on inference of genotype and gene counting as follows: Obligate hétérozygotes (the parents of affected offspring) in each pedigree were genotyped by HLA association and ACTH stimulation hormone testing. Occur¬ rence of the nonclassic deficiency trait in a tested parent identified the presence of a nonclassic de¬ ficiency alíele also on the second haplotype. Con¬ sidering that the second (nontransmitted) haplotypes of known hétérozygotes still represent a Klinika za djecje bolesti REBRO1 and Centar za tipizaciju tkiva REBRO2,
We describe two sisters (40 and 42 years old) heterozygous for adrenoleukodystrophy who have multiple endocrine disorders. In addition to the characteristic neurological symptoms, the younger patient has Addison disease and primary hypothyroidism attributable to autoimmune thyroiditis, and the older one has Graves disease. Both patients have loss of body hair and sparse scalp hair, which have not been reported previously in women heterozygous for adrenoleukodystrophy. After the institution of glucocorticoid replacement therapy, the younger sister, who has adrenal insufficiency, has shown unexpected neurological improvement.
Growth hormone (GH) responses to sleep, insulin hypoglycaemia and arginine infusion. A few children with no apparent cause for their short stature, continue to grow poorly despite normal GH responses (>15mU/L) to pharmacological stimuli. It has been suggested that their GH secretion during sleep may more accurately reflect their true GH reserve. We have compared sleep related GH secretion (GH-Sleep) with GH responses to insulin hypoglycaemia (GH-I) and arginine infusion (GH-Arg.) in 19 children referred to our Growth Clinic. Blood was withdrawn continuously through an indwelling thromboresistant catheter (Cormed SL-65 Continuous Blood Withdrawal Pump) and divided into 15 minute aliquots, throughout approximately 5 hours of EEG monitored sleep. The following morning an, insulin hypoglycaemia/arginine infusion test was performed. GH was measured by radioiuununoassay. 2 patients had normal GH-Arg. responses but GH-Sleep peaks less than 15mU/~. Correlation coefficients, r, for peak serum GH levels were :for GH-I & GH-Sleep 0.55 (p<0.02), GH-Arg. & GH-Sleep 0.52 (p<0.02) and GH-I & GH-Arg. 0.56 (p <0.02). We conclude that sleep studies of GH reserve are indicated only when the results of stimulation tests are inconsistent with clinical findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.